Oncolytics Biotech Inc T.ONC

ONCY bispecific in development (pelareorep x CD3)

[Noteable]

May 2021 - Collaborative preclinical studies with LUMC is evaluating the combination of pelareorep-CD3-bispecific antibody combinations in breast and pancreatic tumor models.

Pelareorep's clinically demonstrated ability to recruit T cells to solid tumors provides a strong rationale for these studies, as CD3-bispecific antibodies are designed to facilitate cancer-killing by simultaneously engaging both T cells and tumor tissue.

Prior preclinical studies in breast and pancreatic cancer models also support this collaboration, as they have shown that the addition of pelareorep to CD3-bispecific antibody therapy results in cancer regression and prolonged survival.

https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-first-quarter-development-highlights-and-financial-results-301286355.html


Roche's Lunsumio is the first CD20xCD3 bispecific antibody approved anywhere.

https://www.fiercepharma.com/pharma/roches-bispecific-blood-cancer-drug-lunsumio-treads-car-ts-turf-global-first-nod

[Noteable]

ONCY's AWARE-1 showed that treatment with pelareorep with (cohort 2) or without (cohort1) atezolizumab led to the conversion of tumors from the more aggressive luminal B to the luminal A subtype, which is associated with improved clinical outcomes Supplementary to the AWARE-1 findings ONCY's pelareprep X CD3 bispecific has pelareorep binding to CD3 on the surface of T cells which then

[Noteable]

"Reovirus and bispecific antibodies are a true tumor-killer combo that would not be effective without each other.” - Dr. Nadine van Montfoort, group leader of viro-immunotherapy of cancer – at the Leiden University Medical Center (LUMC) in the Netherlands. https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/ https://jitc.bmj.com/content/8/2

[westcoast1000]

"Reovirus and bispecific antibodies are a true tumor-killer combo that would not be effective without each other.” - Dr. Nadine van Montfoort, group leader of viro-immunotherapy of cancer – at the Leiden University Medical Center (LUMC) in the Netherlands. This is a very important statement that Noteabele has posted.

[westcoast1000]

Building on my previous post: If the big pharma world collectively accepts the statement of Dr. von Monfoort, our  subjective expected value as a company, in terms of medium term NPV, should perhaps be double what people thought previously, IMHO. 

[askretka]

https://absoluteantibody.com/general/using-bispecific-antibody-reagents-to-further-research/ ---------------------------- The quote can be found in this article. It's only mouse studies so far but so far mouse studies in pelareorep have correlated very well with human trials ----------------------------- Radiation studies recently with pelareorep and radiation were only mice studies as well

[Noteable]

westcoast1000, further to your point and in support of of Dr. von Monfoort's statement supporting the findings of the bisepecific study and other work that ONCY has conducted showing that pelareorep is synergistic with other forms of I/O cancer therapy including checkpoint inhibitors and CAR-T therapy for example, Dr. vaon Monfoort's work adds to the growing evidence that pelareorep in

[Noteable]

The combination of BiTEs/TriTEs with OVs holds the potential for mutual advantages. "Reovirus and bispecific antibodies are a true tumor-killer combo that would not be effective without each other.” - Dr. Nadine van Montfoort, group leader of viro-immunotherapy of cancer – at the Leiden University Medical Center (LUMC) in the Netherlands. Instead of directly focusing on

[Noteable]

This is how one should consider the much broader and increasing potential of pelareorep in combination with multiple cancer agents.